Drug Trial Radar · NCT05179876
A Study Providing Treatment Access in Participants With Pulmonary Hypertension Completing a Parent Study and Having no Other Option
Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
280
Planned (sponsor's estimate)
Start
May 4, 2022
Primary completion
Jan 31, 2027
Study completion Sep 28, 2033
Sponsor
- Lead sponsor
- ActelionJohnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- Jan 5, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 2 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to enable participants with pulmonary hypertension (PH) currently treated with study intervention(s) in a clinical study (parent studies \[NCT03422328, NCT03904693,NCT04565990, NCT02932410, NCT03492177, and NCT04175600\]), to continue to benefit from the intervention after closure of the parent study in case they have no alternative means of access to the study intervention. This study will allow assessment of the long-term safety of each study intervention.
Conditions
- Hypertension, Pulmonary
Interventions
MacitentanDrug
Adult participants will receive oral dose of macitentan 10 milligrams (mg) tablet once daily. Children greater than or equal to (\>=) 2 year to less than (\<) 18 years will be given an oral macitentan dose tailored to their body weight, ensuring an equivalent level of systemic exposure as in adults.
SelexipagDrug
Adult Participant will receive oral dose of selexipag tablet twice daily at the dose strength corresponding to their maintenance dose at the end of their parent study. Available strengths: 200, 400, 600, 800, 1000, 1200, 1400 and 1600 micrograms (µg). Children with body weight category of \>=50 kg will use the tablets at the required dose strength as described for adults. Children with a body weight \< 50 kg will receive tablets for pediatric use (dose strengths: 100 and 150 mcg), twice daily to enable continuation of individually maximum tolerated dose of selexipag according to their body weight category.
Macitentan/Tadalafil FDCDrug
Participants will receive oral FDC of macitentan 10 mg and tadalafil 40 mg once daily during the course of the study as already received in the parent studies.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Frequency of Treatment Emergent Adverse Events (TEAEs)Time frame: Baseline until End of Study (EOS) (up to 84 months)
- Frequency of TEAEs Leading to DiscontinuationTime frame: Baseline until EOS (up to 84 months)
- Frequency of Serious Adverse Events (SAEs)Time frame: Baseline until EOS (up to 84 months)
- Frequency of DeathsTime frame: Baseline until EOS (up to 84 months)
Locations
45 sites in 13 countries. Site status is shown where the registry gives one.
The Republican Scientific-Practical Center ''Cardiology''
Minsk, Belarus · Recruiting
Minsk Regional Clinical Hospital Of The Red Banner Of Labor
Minsk, Belarus · Completed
UZ Leuven
Leuven, Belgium · Completed
University Multiprofile Hospital for Active Treatment- UMHAT Sveta Anna AD
Sofia, Bulgaria · Recruiting
Beijing Anzhen Hospital 1
Beijing, China · Recruiting
Beijing Anzhen Hospital
Beijing, China · Recruiting
The Second Xiangya Hospital of Central South Hospital
Changsha, China · Recruiting
Jiangsu Province Hospital
Nanjing, China · Recruiting
Qingdao Women and Children's Hospital
Qingdao, China · Recruiting
Childrens Hospital of Shanghai
Shanghai, China · Recruiting
The First Affiliated Hospital of Xian Jiaotong University
Xi'an, China · Recruiting
Gottsegen György Országos Kardiológiai Intézet
Budapest, Hungary · Recruiting
Klinika Kardiologii Z Oddzialem Intensywnego Nadzoru Kardiologicznego UM W Bialymstoku
Bialystok, Poland · Recruiting
Szpital Uniwersytecki nr 2 im dr Jana Biziela w Bydgoszczy, Klinika Kardiologii
Bydgoszcz, Poland · Completed
SPSK nr 7 SUM w Katowicach Gornoslaskie Centrum Medyczne im Prof Leszka Gieca
Katowice, Poland · Recruiting
Oddzial Kardiologii Wojewodzki Szpital Specjalistyczny im W Bieganskiego
Lodz, Poland · Completed
Wojewodzki Szpital Specjalistyczny im Stefana Kardynala Wyszynskiego SPZOZ
Lublin, Poland · Completed
SPSK2 PUM Klinika Kardiologii
Szczecin, Poland · Completed
Wojewodzki Szpital Specjalist Osrodek Badawczo Rozwojowy
Wroclaw, Poland · Completed
Wojewodzki Szpital Specjalistyczny we Wroclawiu
Wroclaw, Poland · Recruiting
Scientific and Research Institution of Cardiovascular Diseases Complex Problems
Kemerovo, Russia · Completed
E.Meshalkin National Medical Research Center of the Ministry of Health of the Russian Federation
Novosibirsk, Russia · Recruiting
Federal State Budgetary Institution
Saint Petersburg, Russia · Completed
Institute of Cardiology of Tomsk National Research Medical Center of Rus Academy of Sciences
Tomsk, Russia · Completed
Regional Clinical Hospital No1
Tyumen, Russia · Recruiting
Abdullah, IA
Durban, South Africa · Completed
Dr Kalla
Lenasia, South Africa · Recruiting
Chungnam National University Hospital
Daejeon, South Korea · Recruiting
Gachon University Gil Medical Center
Incheon, South Korea · Recruiting
Seoul National University Hospital 1
Seoul, South Korea · Recruiting
Seoul National University Hospital
Seoul, South Korea · Recruiting
Asan Medical Center
Seoul, South Korea · Recruiting
Samsung Medical Center
Seoul, South Korea · Recruiting
The Catholic University of Korea Seoul St Marys Hospital
Seoul, South Korea · Completed
Kaohsiung Veterans General Hospital
Kaohsiung City, Taiwan · Recruiting
National Cheng Kung University Hospital
Tainan, Taiwan · Recruiting
National Taiwan University Hospital
Taipei, Taiwan · Recruiting
Taipei Veterans General Hospital
Taipei, Taiwan · Recruiting
Chang-Gung Memorial Hospital, LinKou Branch
Taoyuan, Taiwan · Recruiting
Maharaj Nakorn Chiang Mai hospital Faculty of Medicine
Chiang Mai, Thailand · Recruiting
Showing 40 of 45 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.